Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma

被引:73
作者
Tomizawa, Y
Kohno, T
Fujita, T
Kiyama, M
Saito, R
Noguchi, M
Matsuno, Y
Hirohashi, S
Yamaguchi, N
Nakajima, T
Yokota, J
机构
[1] Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Res Inst, Canc Informat & Epidemiol Div, Chuo Ku, Tokyo 1040045, Japan
[4] Gunma Univ, Sch Med, Dept Pathol 2, Gunma 3718511, Japan
[5] Hitachi Ltd, Adv Res Lab, Hatoyama, Saitama 3500395, Japan
[6] Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan
关键词
stage I NSCLC; p53; mutation; expression; prognosis;
D O I
10.1038/sj.onc.1202384
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The association of p53 abnormalities with the prognosis of patients,vith non-small cell lung carcinoma (NSCLC) has been extensively investigated to date, however, this association is still controversial, Therefore, we investigated the prognostic significance of p53 mutations through exons 2 to 11 and p53 protein expression in 103 cases of stage I NSCLC, p53 mutations were detected in 49 of 103 (48%) tumors, Two separate mutations were detected in four tumors giving a total of 53 unique mutations in 49 tumors. Ten (19%) of mutations occurred outside exons 5-8, Positive immunohistochemical staining of p53 protein was detected in 41 of 103 (40%) tumors. The concordance rate between mutations and protein overexpression,vas only 69%, p53 mutations, but not expression, were significantly associated with a shortened survival of patients (P < 0.001), Furthermore, we investigated the correlation between the types of p53 mutations and prognosis. p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P = 0.243 in null mutations), These results indicated that p53 mutations, in particular missense mutations, rather than p53 expression could be a useful molecular marker for the prognosis of patients with surgically resected stage I NSCLC.
引用
收藏
页码:1007 / 1014
页数:8
相关论文
共 44 条
[11]   TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis [J].
deAnta, JM ;
Jassem, E ;
Rosell, R ;
MartinezRoca, M ;
Jassem, J ;
MartinezLopez, E ;
Monzo, M ;
SanchezHernandez, JJ ;
Moreno, I ;
SanchezCespedes, M .
ONCOGENE, 1997, 15 (24) :2951-2958
[12]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[13]  
FONG KM, 1995, CANCER RES, V55, P4268
[14]   K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer [J].
Fukuyama, Y ;
Mitsudomi, T ;
Sugio, K ;
Ishida, T ;
Akazawa, K ;
Sugimachi, K .
BRITISH JOURNAL OF CANCER, 1997, 75 (08) :1125-1130
[15]   ACTIVATING MUTATIONS IN P53 PRODUCE A COMMON CONFORMATIONAL EFFECT - A MONOCLONAL-ANTIBODY SPECIFIC FOR THE MUTANT FORM [J].
GANNON, JV ;
GREAVES, R ;
IGGO, R ;
LANE, DP .
EMBO JOURNAL, 1990, 9 (05) :1595-1602
[16]  
GREENBLATT MS, 1994, CANCER RES, V54, P4855
[17]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[18]  
HORIO Y, 1993, CANCER RES, V53, P1
[19]   INCREASED EXPRESSION OF MUTANT FORMS OF P53 ONCOGENE IN PRIMARY LUNG-CANCER [J].
IGGO, R ;
GATTER, K ;
BARTEK, J ;
LANE, D ;
HARRIS, AL .
LANCET, 1990, 335 (8691) :675-679
[20]   PROGNOSTIC-SIGNIFICANCE OF P53 AND RAS GENE ABNORMALITIES IN LUNG ADENOCARCINOMA PATIENTS WITH STAGE-I DISEASE AFTER CURATIVE RESECTION [J].
ISOBE, T ;
HIYAMA, K ;
YOSHIDA, Y ;
FUJIWARA, Y ;
YAMAKIDO, M .
JAPANESE JOURNAL OF CANCER RESEARCH, 1994, 85 (12) :1240-1246